37682-06-7

Basic information

• Product Name: 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxy-
• Synonyms: 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxy-;8-Methoxy-1H,3H,4H,5H-benzo[d]azepin-2-one;8-Methoxy-4,5-dihydro-1H-benzo[d]azepin-2(3H)-one;1,3,4,5-tetrahydro-8-methoxy-2H-3-benzazepin-2-one;8-Methoxy-2,3,4,5-Tetrahydro-1H-3-Benzazepin-2-One
• CAS NO: 37682-06-7
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.22642
• Mol File: 37682-06-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxy-(37682-06-7)
• EPA Substance Registry System: 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxy-(37682-06-7)

Safety Data

• Hazardous Substances Data: 37682-06-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxyis utilized as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential biological and pharmacological properties. Its ability to interact with specific biological targets makes it a valuable component in the development of new drugs.
Used in Drug Development:
In the pharmaceutical industry, 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxyserves as a building block for the creation of novel therapeutic agents. Its potential applications include the treatment of various diseases and disorders, such as neurological conditions, cardiovascular diseases, and inflammatory processes, owing to its ability to modulate specific biological pathways and targets.
Used in Medicinal Chemistry:
2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxyis employed as a versatile scaffold in medicinal chemistry for the design and optimization of new drug candidates. Its structural features allow for the attachment of various functional groups, enabling the fine-tuning of its biological activity and selectivity towards specific targets.
Used in Drug Discovery:
In the field of drug discovery, 2H-3-Benzazepin-2-one, 1,3,4,5-tetrahydro-8-Methoxyis leveraged as a starting point for the identification of new lead compounds. Its unique chemical properties and potential interactions with biological targets make it an attractive candidate for high-throughput screening and further optimization to develop effective therapeutic agents.

Upstream product

• 4133-34-0 7-methoxyl-2-tetralone 
• 1798-09-0 m-methoxyphenylacetic acid 
• 108962-85-2 N-(2,2-dimethoxyethyl)-2-(3-methoxyphenyl)acetamide 
• 6834-42-0 3-methoxyphenylacetic acid chloride 
• 85175-85-5 2,3-dihydro-8-methoxy-2-oxo-1H-3-benzazepine 

Downstream Products

• 50351-80-9 7-methoxy-2,3,4,5-tetrahydro-1H-benz[d]azepine 
• 720690-73-3 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide 
• 36133-00-3 2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol 
• 1022949-63-8 5-chloro-N₄-((2-((isopropylsulfonyl)phenylamino)pyrimidin-2-yl)amino-N₂-8-methoxy-4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)ethanol 
• 952710-29-1 7-methoxy-3-[2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-2.3.4.5-tetrahydro-1H-benzo[d]azepine 

Relevant articles and documents

Design of oxa-spirocyclic PHOX ligands for the asymmetric synthesis of lorcaserin: Via iridium-catalyzed asymmetric hydrogenation

Phosphine-oxazoline (PHOX) ligands are a very important class of privileged ligands in asymmetric catalysis. A series of highly rigid oxa-spiro phosphine-oxazoline (O-SIPHOX) ligands based on O-SPINOL was synthesized efficiently, and their iridium complexes were synthesized by coordination of the O-SIPHOX ligands to [Ir(cod)Cl]2 in the presence of sodium tetrakis-3,5-bis(trifluoromethyl)phenylborate (NaBArF). The cationic iridium complexes showed high reactivity and excellent enantioselectivity in the asymmetric hydrogenation of 1-methylene-tetrahydro-benzo[d]azepin-2-ones (up to 99% yield and up to 99% ee). A key intermediate of the anti-obesity drug lorcaserin could be efficiently synthesized using this protocol.

TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS

Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor

Abstract A series of novel 2,4-diaminopyrimidine compounds bearing bicyclic aminobenzazepine were synthesized and evaluated for their anti-ALK activities. The activities of these compounds were confirmed in both enzyme- and cell-based ALK assays. Amongst

A new facile synthetic route to [11C]GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor

GSK189254 and its corresponding precursor GSK185071B were synthesized from 3-methoxyphenylacetic acid with 6-chloropyridine-3-carbolic acid or 6-chloronicotinamide in 8 and 7 steps with either 6% or 7% and either 14% or 16% yield, respectively. [11/

Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists

We describe the discovery of small molecule benzazepine derivatives as agonists of human peroxisome proliferator-activated receptor δ (PPARδ) that displayed excellent selectivity over the PPARα and PPARγ subtypes. Compound 8 displayed good PK in the rat a

FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5-tetrahydro-1H-2-benzazepine and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R" represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Bronchorelaxing compounds

A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR9, wherein R9 is H, C1-C6 alkyl; n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S or optionally NR16, wherein R16 is H, C1-C6 alkyl or C2-C6 acyl; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.

Bicyclic fibrinogen antagonists

This invention relates to compounds of the formulae: wherein A1is O, S, N—R1or CHR1; A4is N—R4or CHR4; R2is a sidechain containing an acid or ester group; R1, R4and R5are substituents such as H, alkyl and aryl alkyl, and R6is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.